Bedrijfsoverzicht
Check-Cap Ltd. is a clinical-stage medical diagnostics firm that specializes in developing capsule-based screening technology products designed for medical applications. The company operates within the Healthcare sector, specifically functioning in the Diagnostics & Research industry, which focuses on the development and application of medical testing solutions. As of the latest available data, the company maintains a market capitalization of $12.24M, while its annual revenue and total employee count are not publicly disclosed in the current financial reports. This market capitalization figure indicates that Check-Cap Ltd. is classified as a small-cap entity, suggesting a relatively limited market presence compared to large-cap pharmaceutical or diagnostic peers. The absence of disclosed revenue data alongside a modest market cap highlights that the company is likely in a developmental phase where capital allocation prioritizes research and product development over generating substantial current revenue streams. Consequently, the company's scale reflects an early-stage position in the healthcare diagnostic value chain, relying heavily on future product approvals and commercialization to expand its operational footprint.
Financiële gezondheid
The financial statements for the trailing twelve months show a net income of $-13,624,000, an EBITDA of $-3,756,500, and revenue figures that are not disclosed in the available data. The substantial gap between the reported net income of $-13,624,000 and the EBITDA of $-3,756,500 reveals a cost structure heavily impacted by significant non-operating expenses or interest costs, as the company loses over $9 million between operating earnings and bottom-line net income. The free cash flow stands at $-1,058,125, indicating that the company is currently burning cash rather than generating liquidity, which limits its immediate financial flexibility for capital expenditures or unexpected market opportunities. All three margin metrics—the gross margin, operating margin, and profit margin—are reported at 0.0%, which suggests that the company has either recorded no revenue for the period or that its costs have fully eroded any generated revenue to the point of zero margin reporting. On the balance sheet, the company holds $1.42M in cash against $139,000 in debt, resulting in a debt-to-equity ratio of 3.69, which indicates a highly leveraged position relative to its equity base despite the low absolute debt level. The current ratio is 0.71, meaning current assets are insufficient to cover current liabilities, signaling potential short-term liquidity constraints that require careful management of working capital. Return on Equity is reported at -130.1% and Return on Assets at -20.8%, metrics that reveal that management is currently generating negative returns on both shareholder capital and the total asset base, a common characteristic of clinical-stage companies before product commercialization.
Waarderingsbeoordeling
The trailing P/E ratio and forward P/E ratio are both listed as N/A due to the company's net loss, which prevents the use of traditional earnings-based valuation multiples for comparison with profitable peers. In the absence of a trailing P/E, the price-to-book ratio becomes a primary valuation metric, standing at 2.61, which indicates that the market values the company's equity at more than two and a half times its book value. The price-to-sales ratio and EV/EBITDA of -2.28 are the alternative valuation metrics provided, suggesting that investors are pricing the company based on asset backing and enterprise value rather than current profitability. The stock has traded between a 52-week low of $0.59 and a 52-week high of $3.92, with the current price position relative to this range dependent on the latest trading data not explicitly stated as a single figure. The beta value of 0.79 indicates that the stock's price volatility is lower than the broader market, suggesting that the company's share price moves less aggressively than the overall market index during periods of fluctuation. This lower beta implies that Check-Cap Ltd. may offer a less volatile investment profile compared to high-beta small-cap stocks, though the negative EV/EBITDA of -2.28 underscores the risks associated with unprofitable growth-stage biotech or diagnostic firms.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both reported as N/A, indicating that there is no historical data available to compare current performance against the previous fiscal year. The absence of comparable growth rates makes it difficult to determine whether earnings are growing faster or slower than revenue, as the company has not yet established a track record of consistent financial expansion. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that all available earnings, including the net loss, are theoretically available for reinvestment if profitability were achieved. Consequently, the company's strategy focuses on reinvesting resources into research and development to advance its capsule-based technology rather than providing current income returns to investors. The overall growth and income profile of Check-Cap Ltd. is characterized by a complete lack of current profitability and dividend distribution, relying entirely on future clinical milestones and product launches to create value for shareholders in the healthcare diagnostics sector.